Intercept Pharmaceuticals, Inc. (ICPT) |
|
19.01 -0.14 (-0.73%)
|
02-03 13:55 |
|
Open: |
18.79 |
Pre. Close: |
19.15 |
|
High:
|
19.29 |
Low:
|
18.73 |
|
Volume:
|
191,244 |
Market Cap:
|
787(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 1:47:23 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 22.53  One year: 26.31 |
| Support: |
Support1: 14.56 Support2: 11.64 |
| Resistance: |
Resistance1: 19.29 Resistance2: 22.53 |
| Pivot: |
17.37 |
| Moving Average: |
MA(5): 18.72 MA(20): 16.83
MA(100): 14.96 MA(250): 15.5 |
| MACD: |
MACD(12,26): 1.2 Signal(9): 1 |
| Stochastic oscillator: |
%K(14,3): 95.4 %D(3): 91.9 |
| RSI: |
RSI(14): 72.5  |
| 52-week: |
High: 21.25 Low: 10.81 |
| Average Vol(K): |
3-Month: 723 (K) 10-Days: 562 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ICPT ] has closed below upper band by 17.9%. Bollinger Bands are 51.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
19.29 - 19.36 |
19.36 - 19.45 |
|
Low:
|
18.45 - 18.53 |
18.53 - 18.62 |
|
Close:
|
19 - 19.13 |
19.13 - 19.28 |
|
Company Description |
|
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York. |
Headline News |
Fri, 03 Feb 2023
Barclays PLC Increases Stock Holdings in Intercept ... - MarketBeat
Thu, 02 Feb 2023
State Street Cuts Stake in Intercept Pharmaceuticals (ICPT) - Nasdaq
Tue, 31 Jan 2023
BlackRock Updates Holdings in Intercept Pharmaceuticals (ICPT) - Nasdaq
Wed, 25 Jan 2023
ICPT Stock Pops After Intercept Staves Off Amneal's Ocaliva ... - Investor's Business Daily
Wed, 25 Jan 2023
Do Analysts Agree Wednesday on Intercept Pharmaceuticals Inc (ICPT) Stock's Target Price? - InvestorsObserver
Thu, 19 Jan 2023
Strs Ohio Trims Stock Position in Intercept Pharmaceuticals, Inc ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
41 (M) |
| Shares Float |
34 (M) |
|
% Held by Insiders
|
3.1 (%) |
|
% Held by Institutions
|
81.1 (%) |
|
Shares Short
|
3,530 (K) |
|
Shares Short P.Month
|
3,530 (K) |
Stock Financials |
|
EPS
|
-2.21 |
|
EPS Est Next Qtl
|
-3.45 |
|
EPS Est This Year
|
-13.99 |
|
EPS Est Next Year
|
-11.6 |
|
Book Value (p.s.)
|
2.59 |
|
Profit Margin (%)
|
54.3 |
|
Operating Margin (%)
|
-9 |
|
Return on Assets (ttm)
|
-4 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
16.3 |
|
Gross Profit (p.s.)
|
8.7 |
|
Sales Per Share
|
9.17 |
|
EBITDA (p.s.)
|
-0.8 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-17 (M) |
|
Levered Free Cash Flow
|
-6 (M) |
Stock Valuations |
|
PE Ratio
|
-8.7 |
|
PEG Ratio
|
-0.5 |
|
Price to Book value
|
7.35 |
|
Price to Sales
|
2.08 |
|
Price to Cash Flow
|
-45.62 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
